JAK Inhibitor Succeeds in Giant Cell Arteritis Trial

(MedPage Today) -- WASHINGTON--Giant cell arteritis (GCA) can be successfully treated with the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq), allowing corticosteroids to be withdrawn, results of a phase III trial indicated.
Among...